Research programme: GLP-1 fusion peptide - Ildong Pharmaceuticals

Drug Profile

Research programme: GLP-1 fusion peptide - Ildong Pharmaceuticals

Alternative Names: GLP-1 Fusion Protein GX-G6

Latest Information Update: 20 Oct 2015

Price : $50

At a glance

  • Originator Ildong Pharmaceutical
  • Class Peptides
  • Mechanism of Action Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus; Obesity

Most Recent Events

  • 20 Oct 2015 Preclinical trials in Obesity in South Korea (unspecified route)
  • 20 Oct 2015 Preclinical trials in Diabetes mellitus in South Korea (unspecified route)
  • 20 Oct 2015 Ildong Pharmaceuticals has patent protection for GLP-1 fusion protein in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top